Drugs & Therapy Perspectives

, Volume 19, Issue 10, pp 5–7 | Cite as

Atomoxetine: profile report

  • J. Elia
  • Daniel J. Safer
Drugs and Profile Reports
  • 11 Downloads

Keywords

Attention Deficit Hyperactivity Disorder Methylphenidate Memantine Atomoxetine Rivastigmine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simpson D, Perry CM. Atomoxetine. Pediatr Drugs 2003; 5(6): 407–15Google Scholar
  2. 2.
    Elia J. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416Google Scholar
  3. 3.
    Safer DJ. Atomoxetine: a viewpoint. Pediatr Drugs 2003; 5(6): 416–7Google Scholar
  4. 4.
    Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996 Apr; 35: 409–32PubMedCrossRefGoogle Scholar
  5. 5.
    Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7PubMedCrossRefGoogle Scholar
  6. 6.
    Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901PubMedCrossRefGoogle Scholar
  7. 7.
    Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5):E83–91PubMedCrossRefGoogle Scholar
  8. 8.
    Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50–5PubMedGoogle Scholar
  9. 9.
    Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002 Jul 1; 67(2): 149–56PubMedCrossRefGoogle Scholar
  10. 10.
    Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84PubMedCrossRefGoogle Scholar
  11. 11.
    Kratochvil C, Wernicke JF, Michelson D, et al. Long-term safety of atomoxetine in the treatment of ADHD [abstract]. 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2001 Oct 23–28; Honolulu, 119Google Scholar
  12. 12.
    Atomoxetine (Strattera) for ADHD. Med Lett Drugs Ther 2003 Feb 3; 45 (1149): 11–2Google Scholar
  13. 13.
    Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 109: E39Google Scholar
  14. 14.
    Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, parallel group study of SL1381 (Adderal XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 110: 258–66PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • J. Elia
    • 1
  • Daniel J. Safer
    • 2
  1. 1.Department of PsychiatryUniversity of Pennsylvania, and The Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Departments of Psychiatry and PediatricsJohns Hopkins Medical InstitutionsBaltimoreUSA

Personalised recommendations